Add-on atogepant 60 mg daily reduced monthly migraine days in chronic migraine patients on stable onabotulinumtoxinA.
Adding atogepant to botulinum toxin reduced migraine days in a small study
This Phase 3, multicenter, 24-week, open-label, single arm study evaluated add-on atogepant 60 mg once daily in 75 participants with chronic…
Adding atogepant to botulinum toxin cut migraine days by over 50% for 62% of patients in a study, with most finding it safe and well-tolerat…
Preliminary Italian data show intravenous eptinezumab reduces pain and symptoms in patients with ongoing episodic or chronic migraine attacks.
The Big Discovery:** A preventive migraine drug can start easing pain and light sensitivity during an ongoing attack—in as little as 10 minutes.
This preliminary observational study enrolled 31 patients with episodic or chronic migraine experiencing an ongoing attack in an Italian rea…
For the first time, real-world data shows a migraine prevention treatment can also act with surprising speed to stop an attack that’s alread…
Resting-state fMRI shows reduced brain entropy in episodic and chronic migraine compared to healthy controls.
Brain entropy changes in migraine patients compared to healthy controls
This resting-state fMRI study examined brain entropy in adults with episodic migraine, chronic migraine, and healthy controls. Results indic…
Migraine patients show lower brain complexity in key networks compared to healthy controls, with the biggest drop seen in chronic cases.
Eptinezumab with education reduces migraine days in chronic migraine with medication overuse
Can a migraine drug plus education help people stuck in a pain cycle?
A phase 4 RCT in 608 adults with chronic migraine and medication-overuse headache found eptinezumab 100 mg IV plus brief education reduced m…
A migraine drug plus brief doctor education cut migraine days by about 3 more than education alone in people with chronic migraine and medic…